New CEO after failed deal


Warsaw – Polish insulin and antibiotics maker Bioton S.A. has shuffled its mana­gement board after announcing that an expected deal failed to materialise. In mid-January, after Prokom Investments (Gdynia) proved unable to sell its 33.3% stake in Bioton to Jerzy Starak’s Polpharma, the company’s share price went on a rollercoaster ride as shareholders tried to come to grip with the news, swinging up and down by as much as 40% in trading.
The latest news was accompanied by a communiqué detailing the retirement of Bioton CEO Adam Wilczega, who will remain on its board as Vice-President. “The most important issue is to regain the trust of investors,” said new CEO and Board President Janusz R. Guy. Guy declared that he will verify the structure of the company’s portfolio and focus on products that are guaranteed to grow in value.
According to local media, Bioton needs a EUR 20m investment to survive. At the end of January, Prokom Investments – Bioton’s largest investor – agreed to provide a cash injection of approximately a11m until the end of the year.



Polish antibody development and manufacturing specialist Mabion S.A. more than tripled its revenues in 2011 (€2.5m) compared to 2010 (€0.74m). The increase in turnover mainly resulted from stronger client demand for R&D services...



Polish company Bioton S.A (Warsaw) and Swiss-headquartered generics giant Actavis (Zug) have joined forces to shake up the €12bn world market for recombinant insulins and insulin analogues. At the end of January, Bioton Chairman...



Zug/Warsaw - The fourth largest generics producer and a polish biotech want to create a stir in the market for diabetes drugs. Swiss Actavis and Bioton from Warsaw announced that they have formed a joint venture company for the...



Krakow – Polish Selvita S.A., which offers preclinical drug development services to pharma companies, has been ranked as the No. 1 “Rising Star” of this year’s Fast50 contest. In the programme, analysts from Deloitte Technology...



Warsaw – Poland’s Bioton S.A. has announced it is investing €20m in a new production plant in Szczecin. The biotechnology company is planning to manufacture insulin injection devices in the facility. The project involves the...



Warsaw – Biotech experts want to make the development of pharmaceutical and medical innovations a priority in Poland. At the start of September, members of the Polish Technology Platform for Innovative Medicine recommended that...



Kraków – Selvita SA CEO Pawel Przewiezlikowski announced at the end of July that the Polish drug development and drug discovery service firm is close to achieving profitability. After bagging EUR3.7m through an IPO on Warsaw’s...



Warsaw – Researchers from Lodz and Poznan Universities say Poland needs to update its draft GMO law. “The national current legal situation is complicated,” Prof. Tomas Twardowski told EuroBiotechNews, stressing that while trade...



Krakow – Polish Selvita S.A. is going public. By May, the drug discovery specialist announced it had entered into definite agreements with investors to sell 2.7 million shares for a total of EUR3.75m, resulting in a market...



Szczecin/Greifswald – A team of physical chemists headed by Robert Hoylst from the Polish Academy of Science have improved a method for calculating the migration time of drugs or drug delivery devices introduced into the sol/gel...

Displaying results 1 to 10 out of 108

1-10 Next >

© 2007-2015 BIOCOM



All Events


Product of the week


Current issue

All issues